Skip to main content
Top
Published in: Hepatology International 2/2024

01-03-2024 | Hepatocellular Carcinoma | Editorial

Nomograms should be noted

Authors: Shuntaro Obi, Masao Omata

Published in: Hepatology International | Issue 2/2024

Login to get access

Excerpt

Hepatocellular carcinoma (HCC) is one of the major health problems in the Asian Pacific area [1]. HCC is the sixth most common malignancy worldwide and the third leading cause of cancer-related death [2] .With the improvement of health standards, the elderly account for more than one-third of patients with HCC [3]. Furthermore, the incidence of HCC is estimated to increase by about 59% by 2030, and patients over 65 years of age are expected to account for more than 50% of all HCC patients by that time [4]. Elderly patients are often complicated by multiple diseases, accompanied by an additional age-related decline in physical capacity, and these factors have a significant impact on life expectancy [5]. Furthermore, recent studies have reported that muscle mass has a significant impact on prognosis [6]. Therefore, in predicting the prognosis of hepatocellular carcinoma in the elderly, it is necessary to consider them separately from younger patients. However, current HCC treatment guidelines specify recommended treatment by liver function and tumor factors, but do not take into account differences by age [7]. Currently, there is not enough evidence to guide the treatment of liver cancer in elderly patients. Therefore, in this paper, the authors identified prognostic determinants in elderly HCC patients and developed a new prognostic model to predict overall survival (OS). This article was published in this journal 2023 Apr 17 by Tan et al. [8]. In recent years, nomograms have gained wide acceptance in the field of oncology as a reliable tool for assessing patient prognosis [7]. Nomograms are graphical representations of predictive statistical models for individual patients and have been developed for various types of cancer. Because nomograms have proven to be superior to traditional staging systems that have been used to predict patient outcomes in many cancers, they have been proposed as an alternative or emerging standard to guide treatment strategies for cancer patients. On the other hand, its weaknesses must also be understood [9]. A search of "HCC and nomograms" in PubMed reveals 1178 articles in the past 10 years (Fig. 1). Of these, 46 nomograms were analyzed using Surveillance, Epidemiology, and End Results (SEER), a public database in the United States. These papers are a mix of good and bad. Excellent research papers with a high number of citations include nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma [10] (cited 454), preoperative prediction of microvascular invasion [11] (cited 202), recurrence after liver transplantation [12] (cited 227), recurrence and survival after curative liver resection [13] (cited 199). Nomograms are most effective in predicting a single event in a limited population. Therefore, more accurate results can be obtained by narrowing the target, as seen in the risk of vascular invasion. On the other hand, the predictive probability of individual prognosis, a target with a complex interplay of multiple factors, is lower [14].
Literature
2.
5.
go back to reference Cho E, Cho HA, Jun CH, Kim HJ, Cho SB, Choi SK. A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes. In Vivo. 2019;33(5):1411–1420CrossRefPubMedPubMedCentral Cho E, Cho HA, Jun CH, Kim HJ, Cho SB, Choi SK. A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes. In Vivo. 2019;33(5):1411–1420CrossRefPubMedPubMedCentral
6.
go back to reference Hiraoka A, Otsuka Y, Kawasaki H, Izumoto H, Ueki H, Kitahata S, et al. Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(6):1271–1276. https://doi.org/10.1111/jgh.14058. (Epub 2018 Jan 19 PMID: 29193248)CrossRefPubMed Hiraoka A, Otsuka Y, Kawasaki H, Izumoto H, Ueki H, Kitahata S, et al. Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(6):1271–1276. https://​doi.​org/​10.​1111/​jgh.​14058. (Epub 2018 Jan 19 PMID: 29193248)CrossRefPubMed
Metadata
Title
Nomograms should be noted
Authors
Shuntaro Obi
Masao Omata
Publication date
01-03-2024
Publisher
Springer India
Published in
Hepatology International / Issue 2/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10612-y

Other articles of this Issue 2/2024

Hepatology International 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.